🇺🇸 FDA
Patent

US 8394387

Recombinant modified Bacillus anthracis protective antigen for use in vaccines

granted A61KA61K2039/505A61K2039/53

Quick answer

US patent 8394387 (Recombinant modified Bacillus anthracis protective antigen for use in vaccines) held by The United States of America as Represented by the Secretary of the Department of Health and Human Services expires Mon Mar 07 2033 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America as Represented by the Secretary of the Department of Health and Human Services
Grant date
Tue Mar 12 2013 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 07 2033 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
13
CPC classes
A61K, A61K2039/505, A61K2039/53, A61K39/00, A61P